Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€17.29

€17.29

-2.550%
-0.45
-2.550%
€135.50
 
21.08.25 / Tradegate WKN: A1J1BH / Symbol: AVII / Name: Sarepta / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Sarepta Therapeutics Stock

We can see a decrease in the price for Sarepta Therapeutics. Compared to yesterday it has lost -€0.450 (-2.550%).
With 0 Sell predictions and 2 Buy predictions the community sentiment towards the Sarepta Therapeutics stock is not clear.
Based on the current price of 17.29 € the target price of 135 € shows a potential of 681.02% for Sarepta Therapeutics which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Sarepta Therapeutics stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Sarepta Therapeutics in the next few years

Pros
?
G***** c******* t* c**********
?
M***** P*******
?
C******** o* t** e**********
Cons
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Sarepta Therapeutics vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Sarepta Therapeutics -2.550% -0.832% 51.889% -86.564% -85.015% -83.855% -85.651%
Regeneron Pharmaceuticals Inc. 2.050% 6.156% 10.525% -51.473% -23.773% -16.299% 0.448%
Exact Sciences 0.560% 4.439% -2.513% -24.594% -25.800% 10.020% -40.670%
Incyte Corp. 0.780% 0.838% 29.424% 29.649% 13.512% 0.498% -6.505%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

The financials of Sarepta Therapeutics, traded under the symbol AVII, reflect a complex picture shaped by its positioning in the Biotechnology and Medical Research sector. The company has been heavily investing in research and development, which is crucial in this industry. However, the resulting financial statements indicate significant losses, raising queries about its future performance and viability. While the potential for groundbreaking advancements in treatment options exists, investors must weigh the current financial challenges against future possibilities carefully.

Market Capitalization: With a market capitalization of approximately $12.9 billion, Sarepta has a robust presence in the biotech sector. This positioning facilitates investment opportunities and potential market confidence, reflecting the belief in its future innovations.

Revenue Growth: Revenues for Sarepta totaled about $1.4 billion in the most recent twelve months (TTM). This suggests that the company has viable product lines, delivering growth opportunities despite the ongoing losses.

Comments

Addicted to Incredibox? Sprunki Game is the perfect fix! Play now and start making awesome music!
Show more

For those tackling complex topics like this, CIPD Level 3 Assignment Writing Services can offer valuable support in crafting insightful and well-researched content.
Show more

Prediction Buy
Perf. (%) -84.10%
Target price 135.500
Change
Ends at 01.02.26

I've gotta say, Sarepta's looking pretty intriguing right now. Sure, there's been some turbulence - that patient death in the FDA database is a bit of a gut punch. But let's not throw the baby out with the bathwater, folks. Jim Cramer's take on their 'great science' really resonates with me. They're like a biotech wizard cooking up potentially game-changing treatments for rare diseases. The RNA-targeted therapies? That's some cutting-edge stuff right there. Now, I know the price has been a rollercoaster, but isn't that just part of the biotech thrill ride? Their recent earnings beat and solid guidance hint at a company that's got its ducks in a row. Yeah, it's speculative - what biotech isn't? - but sometimes you've gotta roll the dice to hit the jackpot. With their innovative pipeline and strong financials, I think Sarepta could be a dark horse ready to bolt. Just remember, in the biotech race, it's not always the fastest starter that crosses the finish line first.
Show more

News

Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside: https://www.marketbeat.com/logos/articles/med_20250812115447_brutal-2025-for-sareptaanalysts-still-call-for-179.png
Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside

For Sarepta Therapeutics (NASDAQ: SRPT), 2025 has been nothing short of an unmitigated disaster. The firm owns the only Food and Drug Administration (FDA)-approved gene therapy for the treatment

Sarepta Therapeutics Stock: FDA Reverses Course on Therapy Ban
Sarepta Therapeutics Stock: FDA Reverses Course on Therapy Ban

Sarepta Therapeutics has experienced a whirlwind week as the FDA unexpectedly reversed its recommendation to suspend shipments of Elevidys, the company's gene therapy for Duchenne muscular

Is This Stock a Buy After Soaring by 20% in 1 Day?: https://g.foolcdn.com/editorial/images/825927/doctor-with-patient-talking.jpg
Is This Stock a Buy After Soaring by 20% in 1 Day?

It's been a rough year for Sarepta Therapeutics (NASDAQ: SRPT), a small-cap biotech that develops medicines for rare diseases. The company's shares are down by 88% year to date due to safety issues